Clinical Trial

Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 29, 2024 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.
Summary
The aim of this randomized study is to compare the efficacy and safety of ondanstron weekly with every 3 weeks for the prevention of nausea and vomiting induced by chemotherapy combined with PD-1 blockade.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-08.
Status change: Not Yet Recruiting → Recruiting 2024-02-28
Trial Details
NCT Number NCT06080880
Lead Sponsor Hubei Cancer Hospital
Conditions Nausea With Vomiting Chemotherapy-Induced
Enrollment 98 participants
Start Date 2023-12-01
Primary Completion 2025-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2024-02-29